Objective: We explored the antiviral therapeutic potential of ibudilast (AV411, and its amino analog, AV1013.
Introduction
NeuroAIDS is in essence a glial-driven disease. Microglia and astrocytes harbor the infection and release cellular and viral toxins responsible for bystander injury of neurons [1] [2] [3] [4] . Emerging evidence implies that, apart from peripheral immune dysregulation, opiates can exacerbate the neuropathological effects of HIV type 1 (HIV-1) infection in the central nervous system (CNS) though direct actions on m-opioid receptor (MOR)-expressing glia [5] [6] [7] [8] [9] [10] . The concept that HIV-1 and opiates can enhance CNS neuropathology is supported both experimentally [1] and in patients with HIV-associated neurocognitive disorders (HANDs) [11, 12] . The CNS is preferentially vulnerable to opiate and HIV-1 interactions most likely due to the complexity and interrelatedness of MOR actions across neurons, astroglia and microglia. In fact, glial cells are implicated as the primary mediators of opiate-driven HIV-1 exacerbation seen with acute morphine and Tat [5] , and also perhaps with gp120 [9] co-exposure.
Ibudilast [3-isobutyryl-2-isopropylpyrazolo (1,5-a) pyridine; AV411, MN-166] is a nonselective phosphodiesterase (PDE) inhibitor that has been marketed for over two decades in Japan for the treatment of chronic asthma [13] . Both AV411 and its amidated analog, AV1013, have a low molecular weight (230 Da), with the ability to readily cross the blood-brain barrier [13] , and have pronounced anti-inflammatory and antinociceptive effects [14] [15] [16] [17] that are reported to be principally mediated by glia [16, [18] [19] [20] . AV411 reduces neuroinflammation by elevating cAMP [21] [22] [23] and by decreasing tumor necrosis factor-a (TNF-a) release, which restricts the activity of glia, while promoting the production of the anti-inflammatory cytokine interleukin (IL)-10 and increasing the release of various neurotrophic factors by astrocytes and microglia [18] [19] [20] . In addition, AV411 has been shown to be neuroprotective against lipopolysaccharides-activated microglia and in neuronal injury from excitotoxic ischemia [24, 25] . AV411 reduces postherpetic neuralgia [26] , limits white matter damage following chronic hypoxia [27] , is protective in an oligodendrocyte precursor cell line (CG-4) [21, 23] , and is potentially neuroprotective in multiple sclerosis [28, 29] . Thus, a variety of evidence implicates AV411 in restricting glial inflammation. In addition, a link between epigenetic changes in IL-10 expression in microglia and reinstatement of opiate-induced conditioned place preference suggests a role for glia in mediating lasting changes in drug-seeking behavior [30] . In the context of opiate abuse, AV411 attenuates the effects of opioid withdrawal, limits morphineinduced dopamine release in the nucleus accumbens, and prevents morphine induction of pro-inflammatory cytokine expression [31] .
The beneficial effects of AV411 on drug abuse extend beyond the opiates. We have previously found that both AV411 and AV1013 attenuate methamphetamineinduced locomotor activity and its sensitization [32] , block prime and cue-induced relapse of methamphetamine-maintained responding [33, 34] , and reduce methamphetamine self-administration. In part, because of these and other preclinical data, AV411 is in clinical trials for methamphetamine abuse [35] and for the treatment of opiate withdrawal [36] . Prompted by evidence that AV411 and AV1013 reduces CNS inflammation and addictive behavior, as well as emerging findings that these drugs can also attenuate inflammation in HIV-exposed glia, we evaluated the properties of ibudilast and AV1013 as potential therapies for the management of HIV-associated inflammation and neurodegenerative effects.
Methods
Experiments were conducted in accordance with procedures reviewed and approved by the Virginia Commonwealth University Institutional Animal Care and Use Committee (IACUC).
Reagents and drug treatments
HIV-1 Tat 1-86 IIIB was purchased from ImmunoDX, LLC (Woburn, Massachusetts, USA) and was used at a concentration of 100 nmol/l ($0.8 mg/ml). Soluble Tat levels in HIV-1 patient sera have been measured up to 40 ng/ml [37, 38] . Morphine sulfate was obtained from the National Institute on Drug Abuse and used at a concentration of 500 nmol/l. Ibudilast (AV411) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, California, USA) and AV1013 was obtained from MediciNova (San Diego, California, USA); both were used at 100 nmol/l, 1 mmol/l and 10 mmol/l concentrations. For time-lapse experiments, treatments were done in vitro using murine mixed-glia and neurons in culture. Cells were left untreated or exposed to HIV-1 Tat 1-86 (100 nmol/l) AE morphine sulfate (500 nmol/l). Additionally, the above treatments were challenged with increasing concentrations of AV411 or AV1013. For experiments examining intracellular signaling, murine mixed-glial cultures lacking neurons were treated in vitro with vehicle control (serum-free DMEM) or the same drug treatments as above.
Murine primary cell cultures
Striatal mixed-glial cultures Brains from P0-P1 ICR mouse pups were removed and striata dissected out. Cells were plated at 1.0 Â 10 5 cells/ cm 2 on poly-L-lysine-coated cell culture dishes and grown until confluent in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum.
Striatal neuron cultures E14-E15 ICR embryos were aseptically removed by cesarean section, decapitated, and the striata were dissected from the cerebrum. The neuron-enriched cell isolates were plated at 0.5 Â 10 5 cells/cm 2 onto a bed layer of 9-10-day-old mixed glia. 
Cell viability
Cell viability in mixed-glial cultures was assessed after 12, 24 and 48 h treatment with AV411 and AV1013 at concentrations of 100 nmol/l, 1 and 10 mmol/l using propidium iodide (Molecular Probes, Eugene, Oregon, USA), and viable cells were quantified by flow cytometry using a FACSCanto II flow cytometer (BD Biosciences, Franklin Lakes, New Jersey, USA).
Subcellular localization of p65
Immunofluorescence labeling was performed as described previously [7] . For detailed methods, see Supplemental Digital Content 1 (http://links.lww.com/ QAD/A515).
Statistical analyses
Mean data values and the SEM were calculated for each variable. One-way analysis of variance (ANOVA), followed by Bonferroni's post-hoc test for multiple comparisons, was used to analyze data involving multiple sample groups. For time-lapse microscopy studies, a twoway repeated-measures ANOVA was performed followed by Duncan's post-hoc analysis. A value of P less than 0.05 was designated as statistically significant.
Results

HIV-1 replication in human microglia is attenuated with AV411 and AV1013
The inhibitory potential of AV411 and the amino analog AV1013 on HIV-1 replication in primary human microglia was examined using transient transfection of a Tat-responsive long terminal repeat (LTR) construct with a luciferase reporter. Twenty-four hours after infection, Tat protein expression was increased 2.2 and 2.5-fold in microglia after infection with HIV-1 SF162 alone and with HIV-1 in combination with morphine, respectively, when compared to uninfected control cells ( Fig. 1a ). Exposure to both AV411 and AV1013 caused a significant decrease in Tat protein expression, whereas concurrent exposure with morphine had a minimal effect on the inhibitory action of both AV411 and AV1013 ( Fig. 1a ).
Twenty-four hours after infection, the Tat PCR products shown in the top bands on the agarose gel correlated with the LTR luciferase data, whereas glyceraldehyde 3-phosphate dehydrogenase (GAPDH), shown in the bottom bands, was used as a loading control. Lastly, HIV-1 p24 levels were examined in the supernatant from HIV-1 SF162 -infected microglia by ELISA ( Fig. 1b ). Forty-eight hours post-treatment with morphine caused a significant increase in viral replication when compared to HIV-1 alone. To confirm these initial studies, mRNA expression levels of HIV-1 Tat in virally infected microglia were also examined by RT-PCR ( Fig. 1c ) and nested RT-PCR ( Fig. 1d ) to rule out lack of Tat expression. Exposure with both AV411 and AV1013 caused a significant decrease in viral replication, whereas concurrent exposure with morphine had no significant effect on the inhibitory actions of AV411.
AV411 and AV1013 block synergistic morphine and Tat-induced neurotoxicity in vitro
The therapeutic potential of AV411 and the amino analog AV1013 in attenuating the synergistic interactions seen with opiate abuse-HIV comorbidity in neuronal cell death was examined in neuron mixed-glial co-cultures from murine striatum exposed with Tat AE morphine. A within-subjects design was used, which assesses the same neurons throughout the experiment using a computeraided stage encoder over 72 h, and that greatly reduces interneuron variability and increases the sensitivity of the assay [1] . Neurons in control cultures showed some inherent toxicity in this assay, whereas treatment with Tat (100 nmol/l) for 72 h significantly reduced the survival of isolated striatal neurons as compared with untreated neurons at each time point after 24 h (Fig. 2; Ã P < 0.05 vs. control). The Tat-induced decline in neuronal survival was significantly enhanced with concurrent morphine treatment at each time point after 28 h when compared to the Tat-only condition ( Fig. 2b, d) . At 100 nmol/l, AV411 had no effect on Tat and morphine-mediated neurotoxicity, although at 10 mmol/l concentration, it did show some toxicity ( Fig. 2b and data not shown). Co-administering 1.0 mmol/l AV411 was not toxic and partially reversed Tat-mediated toxicity ( Fig. 2a , dotted line), while significantly preventing the neurotoxic effects of combined Tat and morphine exposure ( Fig. 2b ). AV1013 at a concentration of 100 nmol/l was also not toxic ( Fig. 2c , black line), and although it did not reverse Tat-mediated neuronal cell death ( Fig. 2c , dotted line), it significantly prevented combined Tat and morphinemediated neuronal cell death. At concentrations of 1 and 10 mmol/l, AV1013 was intrinsically neurotoxic and displayed additive neurotoxicity when combined with Tat and morphine ( Fig. 2d and data not shown). Thus, both AV411 and AV1013 can significantly reverse Tat-mediated neuronal cell death when co-exposed to morphine.
AV411 and AV1013 reduce the secretion of proinflammatory cytokines from Tat W morphinetreated cells Activated microglia and astroglia are believed to be centrally involved in the neuronal loss associated with HIV-1 and opiate-induced cytotoxicity as they release pro-inflammatory factors, such as TNF-a, that eventually lead to cognitive deficits and other neuropathology linked to HANDs [40, 41] . In an effort to determine a possible mechanism through which AV411 and the amino analog AV1013 were able to reverse Tat and morphine-mediated neurotoxicity, the release of selective inflammatory cytokines were analyzed. The therapeutic potential of AV411 and AV1013 in attenuating migration inhibitory factor (MIF), a pro-inflammatory cytokine known for its effect on macrophage migration and activation, the proinflammatory mediator TNF-a, and the anti-inflammatory cytokine IL-10 was examined in glial co-cultures from murine striatum exposed with Tat AE morphine. The release of inflammatory molecules was measured in supernatants from mixed-glial cultures after 1 and 8 h treatment with 1 mmol/l AV411 or 100 nmol/l AV1013 ( Fig. 3 ). MIF expression levels were relatively unchanged after 1 h treatment with AV411 or AV1013, when compared with vehicle-treated (control) cells (Fig. 3b ). An 8-h exposure to Tat alone or in combination with morphine caused a significant increase in MIF secretion, and both AV411 and AV1013 significantly reduced this effect. Likewise, 8-h treatment, but not 1-h treatment, with Tat AE morphine elevated TNF-a secretion, and both AV411 and AV1013 returned TNF-a levels to vehicle-treated levels ( Fig. 3c and d) . On the contrary, both AV411 and AV1013 significantly increased IL-10 levels at both 1 and 8 h in the Tat and Tat þ morphine groups, yet they had no effect on IL-10 in the vehicletreated controls ( Fig. 3e and f) . Our data agree with previously published data by others showing an inhibition of inflammatory responses and an increase in antiinflammatory responses by AV411 [18, 25, 42, 43] .
AV411 and AV1013 modulate Tat R morphineinduced nuclear factor-kappa B nuclear translocation Nuclear factor-kappa B (NF-kB) signaling plays an important role in Tat AE morphine-induced cytokine production in glial cultures [7] . It has been reported that AV411 can disrupt transcriptional activity of NF-kB and the stability of nuclear factor of kappa light polypeptide gene enhancer in B-cells, inhibitor a (IkBa) [42] . In an effort to explain how AV411 diminished MIF and TNF-a-induced release by Tat AE morphine treatment, degradation of IkBa and nuclear translocation of NF-kB were determined by western blotting analysis (data not shown), and tracked by immunofluorescence labeling (Fig. 4a, b ). Protein lysates from whole cell controls showed detectable levels of IkBa by western blotting after 60 min, whereas incubation with Tat AE morphine led to the degradation of IkBa. Pretreatment with 1.0 and 10 mmol/l AV411 in the presence or absence of Tat AE morphine led to the degradation of IkBa.
We then determined p65 nuclear localization in mixedglial cell cultures labeled with the astrocyte-specific marker glial fibrillary acidic protein (GFAP) by immunofluorescence ( Fig. 4a ). As expected, we observed p65 nuclear translocation in cells treated with Tat alone or in combination with morphine ( Fig. 4a, b ), whereas treatment with 1.0 and 10 mmol/l AV411 in the presence or absence of Tat AE morphine attenuated p65 nuclear localization after 8 h of treatment. In addition, astroglia displayed morphological changes including cytoplasmic retraction resembling stellation upon treatment ( Fig. 4b ; arrow), which can be caused by increases in cytoplasmic cAMP [44] , and this phenomenon was more noticeable with 10 mmol/l concentrations of AV411. Interestingly, when cells were treated with AV1013, which lacks PDE activity, cytoplasmic retraction/stellation was not observed, suggesting that AV411 was responsible for the morphological changes, as cAMP-dependent pathways can influence important aspects of cellular growth, morphogenesis and differentiation. The data suggest that AV411 and AV1013 can disrupt Tat AE morphine-induced modulation of NF-kB signaling.
Effect of experimental treatments on cell viability
A viability assay was performed in mixed-glial cells at 12, 24, and 48 h after treatment with increasing concentrations of AV411 and AV1013 (Fig. 5 ). Both AV411 and AV1013 showed minimal toxicity and caused negligible cell death after 12 h of treatment. At the highest concentrations tested, 10 mmol/l AV1013 caused an approximately 23% decrease in glial viability after 24 h and an approximately 46% decrease in glial viability after 48 h, whereas 10 mmol/l AV411 caused a loss in glial viability in about a quarter of the cells after 48 h. Importantly, however, beneficial reductions in HIV-1 replication, the release of inflammatory cytokines, and in neurodegeneration were evident at concentrations of AV411 or AV1013 that were an order of magnitude less than concentrations in which cytotoxicity was apparent.
Discussion
Despite the advent of combined antiretroviral therapy (cART), the incidence of neurocognitive complications associated with HIV persists, which partially results from the limited efficiency by which many of these drugs cross the blood-brain barrier [45] . Furthermore, cART does not directly target the inflammatory cascades thought to contribute to HIV encephalitis and HANDs [42] . In fact, recent evidence indicates that the sustained production of Tat protein contributes to chronic immune activation seen in HIV-1-infected individuals maintained on cART [46] , and provided partial justification for our use of Tat in the present study. Moreover, because microglia and astroglia are the principal cell types harboring HIV-1 infection in the brain parenchyma and are the main sources of CNS inflammation, glia are critical targets for therapeutic intervention. Therefore, suppression of neuroinflammation may provide new therapeutic approaches to neuroAIDS. HIV-1 and opiates selectively interact with microglia and astrocytes to enhance the release of pro-inflammatory cytokines [47] [48] [49] and to exacerbate bystander neurotoxicity [5] . The goal of this study was to evaluate the drug ibudilast (AV411), which has already been used clinically for almost two decades, for its ability to prevent viral replication and neuroinflammation, as well as its capacity to restrict the neurotoxic interactions between opiate drugs and HIV-1.
In this study, AV411 and its analog AV1013 inhibited replication of HIV-1 in microglia and additionally restricted Tat AE morphine-induced neurotoxicity: inhibited inflammatory cytokine release; limited the activation HIV-associated inflammation and degeneration therapies El-Hage et al. 1415 of the p65 subunit of NF-kB; and reduced bystander neurotoxicity. The concentrations used to inhibit replication by HIV-1 were between 100 nmol/l and 10 mmol/l, whereas the most efficient concentration for achieving reduced neurotoxicity was 100 nmol/l of AV1013 and 1 mmol/l of AV411. Likewise, 100 nmol/l of AV1013 and 1 mmol/l of AV411 were sufficient to suppress MIF and TNF-a production and to inhibit p65 nuclear translocation. AV411 has a mean half-life of 19 h and inhibits PDE3, PDE4, PDE10 and PDE11 at IC 50 values ranging from approximately 1 to 10 mmol/l [13, 43] . AV441 displayed less neurotoxicity than AV1013 at equivalent concentrations, which might result from the proposed neuroprotective actions of inhibiting PDE [50] . Importantly, reductions in HIV-1 replication, the production of inflammatory cytokines, and in neuronal death were achieved at concentrations of AV411 or AV1013 that were 10-fold lower than concentrations in which cytotoxicity was evident in mixed-glial cultures after prolonged exposure (Fig. 5 ).
In healthy adults, AV411 is generally well tolerated, and with the exception of hyperhidrosis, headache and nausea, no serious adverse side effects have been recorded at the clinically achievable concentration of 59.9 ng/ml AV411 in plasma [51] . Accordingly, the maximum serum concentration of AV411 after oral administration of 10 mg capsule is 30 ng/ml, or about 0.3 mmol/l (www. kyorinpharm.co.jp/prodinfo/medicine/pdf/KETAS_ Capsules.pdf). By administrating 20-30 mg/day, which is the prescribed treatment for asthma [52] , the serum concentration of AV411 is 1 mmol/l or less [18] . The steady-state elimination half-life of AV411 following repeated, daily 50 mg/kg b.i.d. doses is 21-28 h [52] . For the treatment of neurological conditions, higher target doses of 60-100 mg/day have been proposed based on evidence from preclinical and preliminary clinical studies [52] . Initial clinical trials have found ibudilast to be efficacious in the treatment of chronic pain, and disorders such as multiple sclerosis and drug withdrawal and relapse (including methamphetamine and opiates), which may be accompanied by marked neurodegeneration [52] . In a 2-week repeat-dose study comparing the tolerability and pharmacokinetics of ibudilast at 20-50 mg b.i.d. in 12 healthy individuals and 12 diabetic patients, peak ibudilast plasma concentrations approximating 120 ng/ml were obtained [13] . Obtaining this plasma level was well tolerated with gastrointestinal complaints being the most frequently reported, and then only by patients who were also being co-medicated for their diabetes. This peak plasma concentration was within the range of our in-vitro concentrations that inhibited replication of HIV-1 in microglia and reduced neurotoxicity. These observations, and considering that the maximum tolerated dose of ibudilast in humans has not yet been demonstrable [13] , increase consideration of ibudilast's potential clinical evaluation as an adjunct in the treatment of HIV infection and associated neurological complications.
Migration inhibitory factor is a pivotal regulator of innate immunity [53, 54] and regulates immune sensitivity to glucocorticoids [55] . MIF expression can also affect adult neurogenesis, as well as learning and memory, and depression [56] . Within the CNS, astrocytes are the major site of MIF expression [57] , whereas the major site of MIF action is at CXCR2 on macrophages and microglia [58] . Likewise, in the CNS, TNF-a is produced by astrocytes and microglia [59] . Both MIF and TNF-a are considered to play critical roles in the development of various pathological processes in the CNS, including neurodegeneration accompanying HIV-related pathology. MIF is involved in the pathogenesis of inflammatory and infectious diseases, and increased MIF levels are detected in HIV-infected individuals as compared to HIV-negative patients [60, 61] . Moreover, the increases in TNF-a that are associated with HIV-1-infected or activated macrophages and microglia are thought to be a major contributor to HIV-1-induced neuroinflammation, which eventually leads to neuronal damage and cognitive impairment [62] [63] [64] . AV411 was shown by others to inhibit the catalytic and chemotactic functions of MIF [65] , and to suppress TNF-a production by glia [18] ; therefore, AV411 may play a strategic role in modifying direct astrocyte-to-microglial signaling via this pathway.
Transcriptional regulators of the NF-kB/IkB family promote the expression of a multitude of cytokines and chemokines [66] . In addition, HIV-1 can activate NF-kB to promote viral replication [67] . AV411 and AV1013 reduced Tat AE morphine-mediated p65 nuclear translocation and localization. Although the precise mechanism by which AV411 affects NF-kB transcriptional activity remains unknown, we conclude that blocking NF-kB activity by preventing nuclear translocation leads to the inhibition of MIF and TNF-a production. Alternatively, a reduction in p65 nuclear trafficking could result from an increase in IL-10, which is known to inhibit the NF-kB pathway [68] .
Despite the significant ability of AV411 to inhibit HIV-1 replication and Tat-induced neurotoxicity, the mechanisms and cellular targets of AV411's actions are not fully understood. We believe that opiate-HIV-1 synergistic bystander neurotoxicity involves cross-talk between glia by blocking reciprocal positive feedback among glial cell types [1] . Although microglia are the main effectors of neuronal injury, their sustained activation, especially in the context of opiate and HIV-1 co-exposure, appears to be driven by astroglial signals [1, 69] ; the release of cytokines and chemokines, and protein oxidation are not self-sustaining in the absence of input from other cell types [10] , which likely include significant signals from astroglia [1, 7, 8] . Ongoing studies in our laboratory are examining the actions of AV411 and AV1013 independently in each glial type using murine and infective human models. Since AV411 appears to restrict neuroinflammatory processes in both astroglia and microglia, we speculate that by acting in both glial types, AV411 is well positioned to attenuate reverberating feedback cascades between astroglia and microglia, which otherwise sustains neuroinflammation and perhaps drives HIV-1 replication in microglia [1, 70] . Lastly, AV411 markedly attenuated HIV-1 replication and prevented Tat-induced pro-inflammatory cytokine production both in the absence and presence of morphine. AV411 was also able to selectively attenuate morphine and Tat neurotoxic interactions, with less of an effect on neurotoxicity due to Tat alone. Further studies validating these outcomes in more therapeutically relevant settings are needed to determine the utility of AV411 as an adjunctive therapeutic for neuroAIDS or for opiate-HIV-1 comorbidity.
